Laurent Fischer, Adverum CEO

Ad­verum faces murky fu­ture af­ter re­view turns up deep­er safe­ty is­sues for gene ther­a­py

Three months af­ter re­veal­ing that a pa­tient lost sig­nif­i­cant vi­sion in one eye af­ter re­ceiv­ing its ex­per­i­men­tal gene ther­a­py, Ad­verum an­nounced it found the safe­ty is­sues were more wide­spread: Five of 12 pa­tients who re­ceived a high dose of the ther­a­py saw “sim­i­lar clin­i­cal­ly-rel­e­vant events.”

Three re­quired surgery on their treat­ed eye. And all 12 are be­ing rec­om­mend­ed “ag­gres­sive im­munomod­u­la­to­ry treat­ments” to pre­vent fur­ther in­jury.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.